Brokerages Anticipate Silk Road Medical Inc (NASDAQ:SILK) to Post -$0.27 EPS

Brokerages predict that Silk Road Medical Inc (NASDAQ:SILK) will post earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Silk Road Medical’s earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.30). The business is expected to issue its next earnings report on Monday, November 4th.

On average, analysts expect that Silk Road Medical will report full-year earnings of ($2.02) per share for the current year, with EPS estimates ranging from ($2.21) to ($1.83). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.83) to ($0.63). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Silk Road Medical.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.14). The company had revenue of $14.93 million during the quarter, compared to analyst estimates of $13.64 million. The company’s revenue for the quarter was up 92.2% compared to the same quarter last year.

Several brokerages have weighed in on SILK. JPMorgan Chase & Co. began coverage on Silk Road Medical in a research report on Monday, April 29th. They issued an “overweight” rating and a $45.00 target price on the stock. Stifel Nicolaus began coverage on Silk Road Medical in a research report on Monday, April 29th. They issued a “buy” rating and a $44.00 target price on the stock. Zacks Investment Research lowered Silk Road Medical from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America began coverage on Silk Road Medical in a research report on Monday, April 29th. They issued a “neutral” rating and a $43.00 target price on the stock. They noted that the move was a valuation call. Finally, BMO Capital Markets began coverage on Silk Road Medical in a research report on Monday, April 29th. They issued an “outperform” rating and a $40.01 target price on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $43.60.

A number of hedge funds have recently made changes to their positions in SILK. Norwest Venture Partners Xiii LP bought a new position in Silk Road Medical during the second quarter valued at about $119,307,000. TimesSquare Capital Management LLC bought a new position in Silk Road Medical during the second quarter valued at about $18,781,000. Janus Henderson Group PLC bought a new position in Silk Road Medical during the second quarter valued at about $18,751,000. Columbus Circle Investors bought a new position in Silk Road Medical during the second quarter valued at about $1,074,000. Finally, Strs Ohio acquired a new position in shares of Silk Road Medical in the 2nd quarter valued at $92,000. 8.03% of the stock is owned by institutional investors and hedge funds.

NASDAQ SILK traded down $1.88 during trading hours on Friday, hitting $40.97. The company had a trading volume of 212,072 shares, compared to its average volume of 182,464. Silk Road Medical has a fifty-two week low of $30.87 and a fifty-two week high of $51.50. The business has a fifty day moving average of $44.03.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Featured Story: What are the benefits of momentum investing?

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.